Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte subpopulation numbers in female B6C3F1 mice (Q23918640)

2

0 references

R.D. Brown

3

0 references

D.L. Musgrove

4

0 references

D.A. Pettit

5

0 references

A.E. Munson

6

0 references

D.R. Germolec

7

0 references

K.L. White

Toxicology and Applied Pharmacology

8

0 references

language of work or name

1 reference

15 June 2000

0 references

published in

0 references

volume

165

0 references

issue

3

0 references

page(s)

237-244

0 references

on focus list of Wikimedia project

Wikimedia–NIOSH collaboration

0 references

1 reference

2 February 2024

THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Neutrophils isolated from leprosy patients release TNF-alpha and exhibit accelerated apoptosis in vitro

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Comparison of ELISA and plaque-forming cell assays for measuring the humoral immune response to SRBC in rats and mice treated with benzo[a]pyrene or cyclophosphamide

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Immune regulation: a critical link between NK cells and CTLs

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Development of a testing battery to assess chemical-induced immunotoxicity: National Toxicology Program's guidelines for immunotoxicity evaluation in mice

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Expression and kinetics of cytokines determined by intracellular staining using flow cytometry.

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Thalidomide in toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Immunomodulatory assays to study structure-activity relationships of thalidomide

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha.

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Cytokine regulation of disease progression in leprosy and tuberculosis

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Long-lived plasma cells: a mechanism for maintaining persistent antibody production.

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages.

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

A distribution-free test of analysis of variance hypotheses.

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Thalidomide prolongs experimental autoimmune neuritis in Lewis rats

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Thalidomide in dermatology. New indications for an old drug

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Thalidomide inhibits the replication of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Use of Ranks in One-Criterion Variance Analysis

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

I. Immunostimulatory Effect of Thalidomide in Normal C57BL/6 Mice is Compatible with Stimulation of a Highly Connected Central Immune System

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

II. The Effects of Thalidomide Treatment on Autoimmune-Prone NZB and MRL Mice are Consistent with Stimulation of the Central Immune System

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021

Plaque formation in agar by single antibody-producing cells

1 reference

https://api.crossref.org/works/10.1006%2FTAAP.2000.8939

7 January 2021